Haryana to decide on offer of 60 million Sputnik V doses for Rs 1120 per dose

Published On 2021-06-07 04:30 GMT   |   Update On 2021-06-07 13:11 GMT

Chandigarh: The Haryana cabinet will take a final decision after the state government received an offer from a pharmaceutical company based in Malta to provide up to 60 million doses of Sputnik-V vaccine to the state at a cost of Rs 1,120 per dose, Health Minister Anil Vij said on Sunday."We are considering the offer and it will be put up before the state cabinet, which will take a...

Login or Register to read the full article

Chandigarh: The Haryana cabinet will take a final decision after the state government received an offer from a pharmaceutical company based in Malta to provide up to 60 million doses of Sputnik-V vaccine to the state at a cost of Rs 1,120 per dose, Health Minister Anil Vij said on Sunday.

"We are considering the offer and it will be put up before the state cabinet, which will take a final decision," Vij told reporters in Ambala.

The state had floated a global tender for COVID-19 vaccine shots through the Haryana Medical Services Corporation (HMSCL) on May 26.

The tender was closed on June 4, but no bid was received during the period, the government had said in a statement here on Saturday.

However, Malta-headquartered Pharma Regulatory Services Limited has given an expression of interest to the state-run HMSCL to provide doses of Sputnik-V manufactured by the Gamaleya Institute and the Russian Direct Investment Fund (RDIF), it had said.

Sputnik-V is one of the three vaccines approved by India''s drug controller for use in the country.

As per the offer made by the firm, each dose of the vaccine will cost Rs 1,120, the statement said.

The firm has given a timeline of 30 days to supply the first batch of five lakh doses, followed by 10 lakh doses every 20 days till the supply is completed, against a letter of credit issued in its name, the government said.

Many states had recently floated global tenders for COVID-19 vaccine to augment supplies being received by the Centre, as well as to give a boost for vaccination of the 18-44 age group.


Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News